What are Citius Oncology, Inc.'s total assets?

Citius Oncology, Inc. (CTOR) holds $100.7M in total assets, up 10.1% year over year.

How much cash does Citius Oncology, Inc. have?

Citius Oncology, Inc. holds $2.6M in cash and equivalents.

Can Citius Oncology, Inc. cover its short-term obligations?

Its current ratio is 0.50 — current liabilities exceed current assets.

Where does Citius Oncology, Inc.'s balance sheet data come from?

Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Citius Oncology, Inc. CTOR Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q2 '26	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25
Cash and cash equivalents	$2.63M+2,350,466%	$7.3M+6,513,696%	$3.92M+3,504,282%	$112-57.1%	$112-99.7%
Accounts receivable, net	——	——	——	——	——
Inventories	$84.79M+120%	$77.47M+227%	$69.22M+601%	$55.2M—	$38.52M—
Work in process	$6.95M—	$6.95M—	$11.71M—	$8.25M—	——
Finished goods	$15.71M—	$15.69M—	$10.58M—	$8.96M—	——
Prepaid expenses and other current assets	$221.11K-91.8%	$331.66K-87.7%	$1.33M-50.7%	$1.1M+2,601%	$2.7M+4,322%
Total current assets	$29.42M+63.1%	$37.15M+117%	$27.54M+151%	$18.31M+44,569%	$18.04M+19,011%
Deferred tax assets	$11.17M+104%	$10.61M+215%	$9.55M+527%	$7.86M+54.8%	$5.48M+8.0%
Other non-current assets	$71.28M—	$72.83M—	$73.4M—	$73.4M—	——
Total assets	$100.7M+10.1%	$109.97M+21.5%	$100.94M+19.6%	$91.71M+86.4%	$91.44M+87.8%
Accounts payable	$8.88M—	$10.45M—	$13.23M—	$8.67M—	——
Accrued expenses	$4.06M—	$4.06M—	$4.09M—	——	——
Total current liabilities	$58.81M+18.2%	$44.71M+3.0%	$49.49M+51.3%	$52.99M+1,620%	$49.74M+1,664%
Deferred tax liabilities	——	——	——	——	——
Total liabilities	$65.43M—	$51.56M—	$56.08M—	$59.31M—	——
Common stock	400M+300%	400M+300%	400M+264%	400M+167%	100M-33.3%
Additional paid-in capital	$131.44M—	$127.98M—	$108.9M—	$91.43M—	——
Retained earnings	-$96.18M-79.2%	-$69.57M-51.5%	-$64.04M-63.0%	-$59.04M-1,842%	-$53.67M-2,085%
Total stockholders' equity	$35.27M-1.0%	$58.41M+41.5%	$44.87M-2.8%	$32.4M+90.2%	$35.64M+79.6%
Total liabilities and stockholders' equity	$100.7M+10.1%	$109.97M+21.5%	$100.94M+19.6%	$91.71M+86.4%	$91.44M+87.8%
Allowance for Doubtful Accounts	——	——	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	——	——	——	——	——
Indefinite-Lived Research and Development Assets	——	——	——	——	——
Deferred contract costs	——	——	——	——	——
Other Assets	$71.28M—	$72.83M—	$73.4M—	$73.4M—	——
Tax Credit Carryforward Valuation Allowance	——	——	——	——	——
Other Commercial Liabilities	$24.06M—	$4.52M—	$4.09M—	——	——
Accrued Liabilities, Current	$24.06M—	$4.52M—	$4.09M—	——	——
License Payable	$17.65M—	$18.25M—	$22.65M—	$28.4M—	——
Accrued taxes and other expenses	——	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	93M+29.9%	84.8M+18.5%	83.5M+16.7%	71.6M+2,956%	71.6M+2,956%
Common Stock Shares Outstanding	——	——	——	——	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M+900%	10M+900%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$9.3K+30.0%	$8.48K+18.5%	$8.35K+16.7%	$7.16K+4,184%	$7.16K+4,184%
Number of Exercisable Options	11.5M—	11.3M—	1.1M—	5.6M—	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	18.1M—	18.1M—	18.1M—	18.2M—	——
Shares Reserved for Future Issuance Under Stock Plans	——	——	——	——	——
Warrants and Rights Outstanding	——	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	$1.83—	$1.83—	$1.83—	$1.82—	——
Aggregate Amount Of Milestone Payments	——	——	——	——	——
Allowance for doubtful accounts	——	——	——	——	——
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1	——	——	——	——	——
Class of Warrant or Right, Outstanding	——	——	——	——	——
Common stock, capital shares reserved for future issuance	——	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$400M+300%	$400M+300%	$400M+264%	$400M+167%	$100M-33.3%
Common stock, shares issued (in shares)	$92.98M+29.9%	$84.8M+18.5%	$83.51M+16.7%	$71.55M+2,956%	$71.55M+2,956%
Common Stock, Shares, Outstanding	$92.98M+29.9%	$84.8M+18.5%	$83.51M+16.7%	$71.55M+2,956%	$71.55M+2,956%
Deferred Tax Liabilities, Gross	——	——	——	——	——
Deferred income taxes	$2.82M—	$3.05M—	$2.78M—	$2.52M—	——
Deferred Tax Assets, Operating Loss Carryforwards	——	——	——	——	——
R&D credit carryforward	——	——	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	——	——	——	——
Deferred Tax Assets, Valuation Allowance	——	——	——	——	——
Deferred Tax Liabilities, Net	——	——	——	——	——
R&D capitalization	——	——	——	——	——
Excess Stock Shares Outstanding	——	——	——	——	——
Final Milestone Payment	——	——	——	——	——
Inprocess Research And Development Noncurrent	$71.11M—	$72.83M—	$73.4M—	$73.4M—	——
Net Sales Percentage	——	——	——	50%—	——
Payment Against Accounts Payable	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M+900%	$10M+900%
Prepaid marketing	——	——	——	——	——
Prepaid expenses	$3.05M+13.1%	$3.16M+17.1%	$1.33M-50.7%	$1.1M+2,601%	$2.7M+4,322%
Purchase Commitment, Remaining Minimum Amount Committed	——	——	——	——	——
Rate Percentage Of Milestone Payment	——	——	——	——	——
Commitment to spend	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$11.5M—	$11.32M—	$9.78M—	$5.55M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$18.1M—	$18.1M—	$18.1M—	$18.17M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$1.83—	$1.83—	$1.83—	$1.82—	——
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Warrants And Rights Outstanding	——	——	——	——	——
Working Capital	$29.4M—	$7.6—	$21.95M—	——	——
Purchase Obligation	——	——	——	——	——
Unrecorded Unconditional Purchase Obligation	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Citius Oncology, Inc.'s total assets?: Citius Oncology, Inc. (CTOR) holds $100.7M in total assets, up 10.1% year over year.
How much cash does Citius Oncology, Inc. have?: Citius Oncology, Inc. holds $2.6M in cash and equivalents.
Can Citius Oncology, Inc. cover its short-term obligations?: Its current ratio is 0.50 — current liabilities exceed current assets.
Where does Citius Oncology, Inc.'s balance sheet data come from?: Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.